Tucotuzumab celmoleukin

Drug Profile

Tucotuzumab celmoleukin

Alternative Names: EMD-273066; huKS-IL2; KS-IL2; KS-interleukin-2

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EMD Lexigen
  • Developer EMD Lexigen; Merck KGaA
  • Class Antineoplastics; Cytokines; Immunoglobulin fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 15 Aug 2017 EMD Serono terminates a phase II trial in Ovarian cancer because the trial got cancelled and no subjects signed informed consent form in USA (Parenteral) (NCT00408967)
  • 28 Feb 2009 Tucotuzumab celmoleukin is still in phase II development for small cell lung cancer
  • 28 Feb 2009 Discontinued - Phase-II for Ovarian cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top